Re: Timothée Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. 2023;84:4-6.

Luke C Ardolino, Rachel Dear, Andrew J Armstrong, Silke Gillessen, Anthony M Joshua

Abstract readLetterComment

In one paragraph

Article in European urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Luke C ArdolinoGarvan Institute of Medical Research, Sydney, Australia; Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, Australia; St. Vincent's Clinical School, University of New South Wales, Darlinghurst, Australia.

Rachel DearGarvan Institute of Medical Research, Sydney, Australia; Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, Australia; St. Vincent's Clinical School, University of New South Wales, Darlinghurst, Australia.

Andrew J ArmstrongDuke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, USA.

Silke GillessenOncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; Università della Svizzera Italiana, Lugano, Switzerland; Division of Cancer Sciences, University of Manchester, Manchester, UK.

Anthony M JoshuaGarvan Institute of Medical Research, Sydney, Australia; Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, Australia; St. Vincent's Clinical School, University of New South Wales, Darlinghurst, Australia. Electronic address: anthony.joshua@svha.org.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Prostatic Neoplasms, Castration-ResistantDipeptidesHeterocyclic Compounds, 1-RingHumansLutetiumMaleProstate-Specific AntigenRadioisotopesRadiopharmaceuticalsTreatment OutcomeDipeptidesHeterocyclic Compounds, 1-RingLutetiumLutetium-177Prostate-Specific AntigenPSMA-617RadioisotopesRadiopharmaceuticals

Identifiers

PMID37355357

DOI10.1016/j.eururo.2023.04.043

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.